Methodological and Practical Challenges for Personalized Therapies in Non-Small-Cell Lung Cancer

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The successful development of personalized therapy depends on the identification of a specific molecular target that drives cancer growth and the subsequent validation of a clinically applicable biomarker molecular test. In non-small-cell lung carcinomas (NSCLCs), analysis of molecular changes is best exemplified by treating patients with tyrosine kinase inhibitors (TKIs) when their tumors harbor activating epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) gene rearrangements. This chapter describes the important methodological and practical issues that represent significant challenges for personalized therapy of NSCLC. The routine utilization of advanced technologies and molecular information, including the application of the NGS tools, coupled with appropriate data management and analysis, may help us to better develop personalized therapies in lung cancer.

Original languageEnglish (US)
Title of host publicationCancer Consult
Subtitle of host publicationExpertise for Clinical Practice
PublisherWiley-Blackwell
Pages480-485
Number of pages6
ISBN (Electronic)9781118589199
ISBN (Print)9781118589212
DOIs
StatePublished - Jun 20 2014

Keywords

  • Anaplastic lymphoma kinase (ALK)
  • Epidermal growth factor receptor (EGFR)
  • Non-small-cell lung carcinomas (NSCLCs)

ASJC Scopus subject areas

  • General Medicine

Fingerprint

Dive into the research topics of 'Methodological and Practical Challenges for Personalized Therapies in Non-Small-Cell Lung Cancer'. Together they form a unique fingerprint.

Cite this